Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.32 |
| ▸ | CPT1A | P50416 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15021656 | 1.00 | KMT2A (0.37) | KMT2AS1PR1L3MBTL1CCNT1CDK9 | |
| SCHEMBL15021296 | 0.95 | KMT2A (0.38) | KMT2AS1PR1L3MBTL1CCNT1CDK9 | |
| SCHEMBL2226746 | 0.95 | KMT2A (0.38) | KMT2AS1PR1L3MBTL1CCNT1CDK9 | |
| SCHEMBL2224861 | 0.95 | KMT2A (0.39) | KMT2AS1PR1L3MBTL1CCNT1CDK9 | |
| SCHEMBL15021708 | 0.95 | KMT2A (0.39) | KMT2AS1PR1L3MBTL1CCNT1CDK9 | |
| SCHEMBL15021634 | 0.95 | KMT2A (0.38) | KMT2AS1PR1L3MBTL1P2RY12CPT1A | |
| SCHEMBL2226615 | 0.95 | KMT2A (0.38) | KMT2AS1PR1L3MBTL1P2RY12CPT1A | |
| SCHEMBL15021217 | 0.92 | ROCK2 (0.32) | KMT2AS1PR1CPT1AMEN1 | |
| SCHEMBL2226520 | 0.92 | S1PR1 (0.34) | S1PR1CPT1AGRIN2B | |
| SCHEMBL2226920 | 0.89 | S1PR1 (0.38) | KMT2AS1PR1L3MBTL1P2RY12MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846691-B2 | Heterocyclic carboxylic acid derivatives having a 2,5,7-substituted oxazolopyrimidine ring | SANOFI (FR) | 2014-09-30 | — | — | US | claimed |
| EP-2523959-B1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI SA (FR) | 2013-11-27 | — | — | EP | claimed |
| US-20130158051-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI (FR) | 2013-06-20 | — | — | US | claimed |
| EP-2523959-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI (FR) | 2012-11-21 | — | — | EP | claimed |
| WO-2011086078-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | WO | claimed |
| US-8846691-B2 | Heterocyclic carboxylic acid derivatives having a 2,5,7-substituted oxazolopyrimidine ring | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| US-8846691-B2 | Heterocyclic carboxylic acid derivatives having a 2,5,7-substituted oxazolopyrimidine ring | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| US-8846691-B2 | Heterocyclic carboxylic acid derivatives having a 2,5,7-substituted oxazolopyrimidine ring | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| EP-2523959-B1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI SA (FR) | 2013-11-27 | — | — | EP | disclosed |
| US-20130158051-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI (FR) | 2013-06-20 | — | — | US | disclosed |
| US-20130158051-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI (FR) | 2013-06-20 | — | — | US | disclosed |
| EP-2523959-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI (FR) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011086078-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011086078-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158051-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | OXGR1, DPYD, FGF2 | KMT2A 2818/4885S1PR1 2691/4885L3MBTL1 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.